PharmaMar, a pharmaceutical company specializing in the discovery of marine-sourced antitumor drugs, has released the results of MI130004, a novel antibody drug conjucate (ADC) combining trastuzumab with PM050489, a molecule of marine origin (1).
The antitumor activity was analyzed in breaOriginal Article
